Skip to content
Screener

Sutro Biopharma STRO Q2 2026 earnings

Reported August 12, 2026 · Before market open

Revenue$9.8MMiss by $2.1M
EPS-$2.33Miss by $0.14
Revenue estimate$12.0M
EPS estimate-$2.19

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$13.6M
EPS estimate-$1.66

Financials

Q2 2026

Income statement

See full
Revenue$9.8M-84.6%
Operating income-$29.9M-794%
Net income-$38.5M-235%
EPS (diluted)-$2.33-72.6%

Balance sheet

See full
Cash & equivalents$54.3M-15.1%
Total debt$10.8M-45.0%
Total equity-$103.3M-222%
Total assets$194.5M-25.9%

Cash flow

See full
Operating cash flow-$38.3M+14.4%
CapEx$256.0K—
Free cash flow-$38.5M+13.8%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$274.58M+258%
Enterprise value$231.03M+672%
P/S6×+5.3×

Profitability

See full
Operating margin-319.6%+540pp
Net margin-395.2%+18,070pp
FCF margin-318.2%+159pp

Returns & leverage

See full
Current ratio3.3×+0.2×

Segments

By product

See full
Materials Supply$4.4M-20.9%
Ongoing Performance Related To Unsatisfied Performance Obligations$4.2M-91.7%
Financing Component On Unearned Revenue$516.0K-38.0%
Research And Development Services$495.0K-18.7%

FAQ

When did Sutro Biopharma report Q2 2026 earnings?
Sutro Biopharma (STRO) reported Q2 2026 earnings on August 12, 2026 before market open.
What were Sutro Biopharma's Q2 2026 revenue and EPS?
Sutro Biopharma reported revenue of $9.8M and eps of $-2.33 for Q2 2026.
Did Sutro Biopharma beat estimates in Q2 2026?
Revenue missed the consensus estimate of $12.0M by $2.1M. EPS missed the consensus estimate of $-2.19 by $0.14.
How did Sutro Biopharma's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 84.6% from $63.7M a year earlier and eps declined 1564.3% from $-0.14.
Where can I find Sutro Biopharma's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-345733) and the 10-Q periodic report (0001193125-26-345748) directly on SEC EDGAR. The filing index links above go to sec.gov.